Takeda Wins FDA Nod For ORZEYFUL, First Orexin Therapy For Narcolepsy Type 1

Takeda (TAK) announced FDA approval of ORZEYFUL, an oral orexin receptor 2 (OX2R) agonist, for treating narcolepsy type 1 (NT1) in adults. This regulatory milestone is a positive catalyst for the company’s product pipeline and commercialization prospects.

Analysis

Takeda (TAK) announced FDA approval of ORZEYFUL, an oral orexin receptor 2 (OX2R) agonist, for treating narcolepsy type 1 (NT1) in adults. This regulatory milestone is a positive catalyst for the company’s product pipeline and commercialization prospects.